Last updated on April 16, 2014 at 17:13 EDT

AstraZeneca Fourth Quarter and Full-Year 2011 Results – Interviews

February 2, 2012

LONDON, February 2, 2012 /PRNewswire/ –

AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price
intervention had reduced its revenues by about $1bn as it announced further restructuring
alongside its full-year results.

In an interview on http://www.cantos.com, David Brennan, CEO, discusses AstraZeneca’s
portfolio performance including Brilinta and Crestor, and the prospects for the pipeline
in light of recent disappointments.

He also reaffirms his strong commitment to returning cash to shareholders.

Also interviewed about the rationale behind the latest phase of the restructuring,
Martin Mackay, President, R&D, said:

“We have to be a very flexible organisation to make sure that we’re dynamic enough to
work in the environment that we work in but also produce great medicines.”

Tony Zook, EVP, Global Commercial, also talks about his confidence in AstraZeneca’s
ability to deliver top line performance and the importance of emerging markets for future

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior
company executives. If you would like to contact us, please email
prnsupport@merchantcantos.com or phone +44-207-936-1352.

SOURCE AstraZeneca

Source: PR Newswire